B of A Securities Maintains Buy on Intellia Therapeutics, Raises Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Greg Harrison maintains a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) and raises the price target from $89 to $91.

June 13, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Intellia Therapeutics and raises the price target from $89 to $91.
The news of B of A Securities maintaining a Buy rating and raising the price target for Intellia Therapeutics is positive for the company's stock. This indicates that the analyst believes the stock has potential for growth and is a good investment. This news is highly relevant to NTLA as it directly pertains to the company's stock and is important for investors to consider. The confidence in this analysis is high as it is based on the expert opinion of a B of A Securities analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100